REGENXBIO Inc.

REGENXBIO Inc.

RGNXNYSE / NASDAQHealthcareSmall cap

$7.16-$0.02 (-0.3%)

Last close · Data as of Nov 20, 2026

Market cap
$355.7M
P/E
-1.8x
EV / EBITDA
-3.0x
Revenue
$170.4M
Net margin
-113.8%
ROCE
-48.1%

-34.1% over the last year

REGENXBIO Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-3.2%
3M
-35.3%
6M
+19.9%
1Y
-34.1%
5Y
-78.6%

52-week range

Day change -$0.02 (-0.3%) from $7 to $7 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in RGNX, bought on each weekday since 2021.

News & filings

What REGENXBIO filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 194 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue more than doubled in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.

Read moreShow less

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Sector
Healthcare
Shares outstanding
50.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$355.7M
P/E
-1.8x
P/B
3.5x
EV / EBITDA
-3.0x
EV / Sales
2.3x
P/S
2.1x
52-week high
$15.98
52-week low
$5.65

Profitability

Operating margin
-94.6%
Net margin
-113.8%
EBITDA margin
-78.2%
ROE
-188.7%
ROCE
-48.1%
ROIC
-83.0%
ROA
-42.8%
Asset turnover
0.38

Growth

Revenue
$170.4M
Revenue growth, 1Y
104.5%
Revenue CAGR, 3Y
14.8%
Net profit growth, 1Y
-14.6%
Free cash flow
-$126.4M

Solvency

Current ratio
2.38
Debt / Equity
0.72
Debt / Assets
0.16
CFO / Net profit
0.64
Cash / Market cap
9.7%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$170.4M
Cost of revenue$20.3M
Gross profit$150.1M
Operating expenses$311.3M
Research and development$228.3M
Selling, general and administrative$82.9M
Operating income-$161.2M
Interest and other-$32.7M
Pretax income-$193.9M
Tax and other$0.00
Net income-$193.9M

Revenue and net profit

Revenue grew 104.5% in FY2025; net profit is the dashed line.

REGENXBIO Inc. revenue and net profit by fiscal year
REGENXBIO Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$112.7M-$280.3M
FY2023$90.2M-$263.5M
FY2024$83.3M-$227.1M
FY2025$170.4M-$193.9M

Cash flows

FY2025: -$124.0M from operations, -$126.4M free after investment (dashed).

REGENXBIO Inc. operating and free cash flow by fiscal year
REGENXBIO Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$207.5M-$238.2M
FY2023-$218.4M-$228.4M
FY2024-$173.1M-$175.6M
FY2025-$124.0M-$126.4M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$170.4M+104.5%1Y
EBITDA
-$133.3M
Net profit
-$193.9M
Cash from operations
-$124.0M
Free cash flow
-$126.4M
Revenue CAGR, 3Y
14.8%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$170.4M-$133.3M-$193.9M-$126.4M-188.7%+104.5%-14.6%

Monthly returns

Month-by-month returns of RGNX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$453.0M
Liabilities$350.3M
Equity$102.7M
Paid-in capital$1.2B
Retained earnings-$1.1B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; RGNX highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. REGENXBIO Inc. (this company)2.3x

Not shown (no positive earnings and no EV / Sales): Perspective Therapeutics, Inc., Atea Pharmaceuticals, Inc., Greenwich LifeSciences, Inc., Larimar Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
REGENXBIO Inc.RGNXthis company$355.7M-1.8x3.5x-188.7%-3.0x
Delcath Systems, Inc.DCTH$372.5M138.0x3.3x2.4%327.0x
Perspective Therapeutics, Inc.CATX$370.7M-3.6x1.8x-49.8%-3.4x
Puma Biotechnology, Inc.PBYI$356.8M11.5x2.7x23.9%6.7x
Atea Pharmaceuticals, Inc.AVIR$353.7M-2.2x1.3x-57.5%-1.4x
Greenwich LifeSciences, Inc.GLSI$347.1M-22.0x137.0x-623.1%—
Larimar Therapeutics, Inc.LRMR$341.8M—4.4x-212.2%—
Enanta Pharmaceuticals, Inc.ENTA$341.1M-4.2x5.3x-126.5%-5.1x
Verastem, Inc.VSTM$339.2M-1.6x5.9x-366.2%-1.1x
Peer median—-2.2x3.9x-92.0%-1.3x

Year-to-date ROI

RGNX since 1 January, against earlier years.

Historical volatility

RGNX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

REGENXBIO Inc. operating margin by fiscal year
REGENXBIO Inc. operating margin by fiscal year
DateOperating margin
FY2022-233.2%
FY2023-297.1%
FY2024-277.5%
FY2025-94.6%
LineFY2025
Cost of revenueCost Of Revenue$20.3M
Gross profitGross Profit$150.1M
Operating expensesOperating Expense$311.3M
Research and developmentResearch And Development$228.3M
Other operating expensesOther Operating Expenses$180.0k
Provision for doubtful accountsProvision For Doubtful Accounts$0.00
Total expensesTotal Expenses$331.6M
Pretax incomePretax Income-$193.9M

Learn while you research

Academy chapters picked for REGENXBIO Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing105% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →